Related by context. All words. (Click for frequent words.) 68 onset atrial fibrillation 65 fibrinolytic therapy 65 hypogonadal men 65 electrical cardioversion 64 fibrinolysis 64 postintervention 64 plasma uric acid 63 asystole 63 β blockers 63 beta blocker therapy 63 reintervention 63 HbA1c levels 63 reinfarction 63 reperfusion 63 lispro 62 serum phosphorus 62 LVEF 62 abciximab 62 tenecteplase 62 occluded catheters 62 paclitaxel eluting stents 62 lipid lowering therapy 62 antiarrhythmic drug 61 intravenous diuretics 61 HBeAg seroconversion 61 left ventricular dysfunction 61 antiarrhythmic drugs 61 perioperatively 61 μmol L 61 alteplase 61 reperfusion therapy 61 NYHA class 61 infarct size 61 DAPT 61 NYHA functional class 61 glycated hemoglobin levels 61 idraparinux 61 LMWH 61 VT VF 61 nicardipine 61 microalbuminuria 61 mL kg 61 recanalization 60 cardioversion 60 ejection fractions 60 atrioventricular block 60 Secondary endpoints 60 infliximab 60 asymptomatic carotid stenosis 60 octreotide LAR 60 CR nPR 60 MACCE 60 NPH insulin 60 atrial fibrillation AF 60 oral anticoagulation 60 pCR 60 nondiabetic patients 60 serum phosphate levels 60 mL/min/#.# m 2 60 crossclamp 60 PSADT 60 OPCAB 60 biochemical recurrence 60 salmeterol fluticasone 60 periprocedural 60 airflow obstruction 60 systolic dysfunction 60 unfractionated heparin 60 systolic function 60 hemodialysis patients 60 serum creatinine levels 60 undetectable HBV DNA 60 endoscopic remission 60 cerebrovascular events 60 serum testosterone 60 ventricular fibrillation VF 60 tirofiban 59 paroxysmal AF 59 left ventricular systolic 59 PSA nadir 59 hemoglobin A1c levels 59 posttreatment 59 IFN beta 59 QRS duration 59 eptifibatide 59 tiotropium 59 dobutamine 59 intact parathyroid hormone 59 bosentan 59 undetectable HCV RNA 59 leukocyte count 59 Kaplan Meier analysis 59 cerebral perfusion 59 QTcF 59 ischemic cardiomyopathy 59 prodromal symptoms 59 LV dysfunction 59 CsA 59 creatinine clearance 59 amiodarone 59 VAPRISOL 59 coronary revascularization 59 CK MB 59 elective PCI 59 adalimumab 59 alanine aminotransferase ALT 59 myocardial reperfusion 59 BYSTOLIC 59 posttransplant 59 insulin detemir 59 neointimal 59 OADs 59 decitabine 59 complete cytogenetic response 59 locomotor activity 59 TAXUS Express Stent 59 biochemical relapse 58 adrenalectomy 58 BENICAR HCT 58 refractory ischemia 58 FOLFOX4 58 Lamictal XR 58 intracoronary 58 XIENCE V PROMUS Stent 58 6MWD 58 renal cysts 58 etanercept 58 HSCT 58 hyperalgesia 58 glomerular filtration 58 DMARD 58 rebleeding 58 serum phosphorous 58 atrial pacing 58 IFN α 58 primary percutaneous coronary 58 partial remissions 58 certolizumab 58 rtPA 58 EDSS scores 58 DAS# remission 58 ischaemia 58 EXJADE 58 saphenous vein grafts 58 revascularization procedures 58 Hb levels 58 irbesartan 58 hemoglobin Hb 58 neointimal hyperplasia 58 serum cortisol 58 postprocedure 58 nmol liter 58 revascularisation 58 hypoperfusion 58 aspartate aminotransferase AST 58 uM 58 olmesartan 58 systemic corticosteroid 58 eplerenone 58 bypass grafting 58 postoperative AF 58 intravenous cyclophosphamide 58 P = .# 58 postoperative complication 58 corticosteroid therapy 58 bradycardia 58 mucosal healing 58 ximelagatran 58 serum urate 58 vernakalant 58 radical nephrectomy 58 transthoracic 58 chlorambucil 58 CrCl 58 biphasic insulin aspart 58 hypokalemia 58 bronchodilation 58 ventricular function 58 thromboembolism 58 mcg QD 58 occlusive disease 58 dosage regimens 58 timepoints 58 CCyR 58 left ventricular LV 58 echocardiographic 58 interquartile range 58 Perforomist Inhalation Solution 58 troponin T 58 blood glucose concentrations 57 perioperative mortality 57 invasive angiography 57 PSVT 57 circulating EPCs 57 fondaparinux 57 platelet reactivity 57 sirolimus eluting stents 57 intima media thickness 57 neurologic progression 57 Postoperative 57 systolic hypertension 57 p = NS 57 vasopressor 57 dexmedetomidine 57 glycosylated hemoglobin HbA1c 57 VELCADE melphalan 57 cardiovascular hospitalization 57 atorvastatin #mg 57 thromboembolic events 57 rFVIIa 57 BENICAR 57 symptomatic VTE 57 pg mL 57 nonresponders 57 idarubicin 57 QTc prolongation 57 aminotransferase levels 57 pamidronate 57 atazanavir ritonavir 57 imatinib therapy 57 sinus tachycardia 57 certolizumab pegol 57 acute myocardial infarction AMI 57 QT intervals 57 complete cytogenetic 57 ischemia driven 57 contractile function 57 postdose 57 elevated IOP 57 lacosamide 57 STEMI patients 57 inotropic agents 57 thrombolysis 57 subclinical hypothyroidism 57 stent implantation 57 NIHSS score 57 Subgroup analysis 57 corticosteroid dose 57 serum calcium levels 57 binary restenosis 57 desvenlafaxine succinate 57 HOMA IR 57 lymphocytosis 57 tamsulosin 57 clinically meaningful improvement 57 tapentadol ER 57 aripiprazole 57 sotalol 57 hypoxemia 57 flecainide 57 myocardial infarction 57 abacavir lamivudine 57 glucose homeostasis 57 serum uric acid 57 neostigmine 57 tumor resection 57 sirolimus stent 57 preserved ejection fraction 57 EBRT 57 APTIVUS r 57 inotropic 57 overt nephropathy 57 thrombocytopenic 57 diastolic dysfunction 57 4mg/kg 57 plasma glucose 57 virological response 57 bezafibrate 57 systolic BP 57 infarcted myocardium 57 oral corticosteroids 57 GH deficiency 57 angiographic restenosis 57 CIMZIA TM 57 virologic failure 57 ALND 57 paroxysmal atrial fibrillation 57 peginterferon 57 β cell 57 mg kg dose 57 L dopa 57 progression TTP 57 stable angina 57 inhaled budesonide 57 HbA 1c 57 spontaneous circulation ROSC 57 placebo p 57 coronary stenosis 57 mmol l 57 PASI scores 57 revascularized 57 ACTEMRA TM 57 trabeculectomy 57 mild renal insufficiency 57 euthyroid 57 atheroma volume 57 titration phase 57 sirolimus 57 Thal Dex 57 autoregulation 57 Brinavess 57 IOP lowering 57 nodular partial response 57 hemodynamically significant 57 % Confidence Interval 57 NSTEMI 57 serum calcium 57 lamotrigine 57 antiangiogenic therapy 57 tricuspid regurgitation 57 T2DM 57 hypothermic circulatory arrest 57 GnRH agonist 57 LEXIVA r 56 hsCRP levels 56 graft occlusion 56 epoetin alfa 56 myocardial infarction MI 56 CRp 56 IELT 56 intraventricular 56 unfractionated heparin UFH 56 thrombotic complications 56 serum testosterone levels 56 bowel resection 56 Dronedarone 56 losartan 56 nadolol 56 dacarbazine 56 systemic corticosteroids 56 NMIBC 56 transaminases 56 severe exacerbations 56 postoperatively 56 artery stenosis 56 placebo p = 56 symptom exacerbation 56 perioperative complications 56 drug eluting stent implantation 56 aminotransferases 56 Atrial 56 mg QD 56 rt PA 56 antihypertensive therapy 56 RVOT 56 ipsilateral stroke 56 HbA 1c levels 56 Hypotension 56 macroalbuminuria 56 noninferior 56 colectomy 56 esomeprazole 56 QTc intervals 56 normothermic 56 concomitant AEDs 56 UA NSTEMI 56 androgen deprivation 56 Elitek 56 pmol L 56 titrated glipizide 56 β blocker 56 amisulpride 56 elevated troponin 56 bivalirudin 56 achieved PASI 56 lenalidomide dexamethasone 56 T1DM 56 CIMZIA ™ 56 complete remissions 56 transaminase levels 56 pressor response 56 paricalcitol 56 cTnI 56 reoperation 56 rimonabant #mg 56 Primary endpoints 56 preintervention 56 MitraClip device 56 nonfatal MI 56 ACTH 56 recurrent VTE 56 radiotherapy RT 56 ventricular dysfunction 56 Cmax 56 radiographic progression 56 triiodothyronine 56 normothermia 56 serum concentrations 56 isoproterenol 56 revascularizations 56 thyrotropin 56 % CI #.#-#.# [003] 56 biliary tract cancer 56 #mg/day [001] 56 ejection fraction EF 56 elevated creatinine 56 azacytidine 56 anticoagulation 56 SCr 56 allopurinol 56 active comparator 56 ventricular tachycardia VT 56 rhTSH 56 renal function 56 primary patency 56 serum phosphate 56 anastomotic leak 56 TACE 56 ULORIC 56 calcineurin inhibitor 56 glargine 56 haematologic 56 cis retinoic acid 56 NIHSS 56 PRADAXA #mg 56 Events MACE 56 TAXUS Stent 56 postoperative bleeding 56 thyroglobulin 56 ibandronate 56 stent binary restenosis 56 bypass graft CABG surgery 56 extubation 56 nonobstructive CAD 56 #mg doses [002] 56 MULTAQ 56 adrenal function 56 FDA defined valvulopathy 56 subcutaneous insulin 56 renal dysfunction 56 prospectively defined 56 myocardial 56 remission CR 56 VIIBRYD 56 FOLFOX6 56 LVSD 56 sirolimus eluting stent 56 oral antidiabetic medication 56 metabolic parameters 56 adjunctive placebo 56 laboratory abnormalities 56 ng dL 56 noninferiority 56 serum ALT 56 pulseless electrical activity 56 tolvaptan 56 corrected QT interval 56 dystrophin expression 56 ribavirin RBV 56 TEAEs 56 SGRQ 56 generalized seizures 56 bolus injection 56 cytopenias 56 liver histology 56 alanine aminotransferase 56 revascularization 56 unstable angina pectoris 56 hyperglycaemia 56 angioplasty stenting 56 Secondary endpoints included 56 stented artery 56 sUA 56 thrombolytics 56 rocuronium 56 status epilepticus 56 timepoint 56 AGILECT R 56 underwent resection 56 NSTE ACS 56 cinacalcet 56 HF hospitalization 56 percutaneous intervention 56 radioiodine therapy 56 nonoperative treatment 55 QTc 55 CDAI 55 caspofungin 55 estimated glomerular filtration 55 thromboembolic 55 Target Lesion Revascularization TLR 55 upper gastrointestinal bleeding 55 postoperative atrial fibrillation 55 Hb A1C 55 mdx mice 55 aortic coarctation 55 quetiapine 55 dysfunction LVSD 55 INVEGA ® 55 A1c levels 55 hepatic metastases 55 vasodilators 55 ziprasidone 55 morphometric vertebral fractures 55 monophasic 55 preoperative PSA 55 median PFS 55 Secondary endpoints include 55 lipid lowering medications 55 antiretroviral naive 55 rosuvastatin #mg 55 luteal phase 55 pramipexole 55 imipenem 55 biventricular pacing 55 ADHF 55 #.#mmol L [002] 55 plus dexamethasone 55 T2 lesions 55 recombinant tissue plasminogen 55 diameter stenosis 55 tachyarrhythmia 55 preoperatively 55 post operatively 55 revascularization procedure 55 attain statistical significance 55 relapsed MM 55 lipid lowering drugs 55 hemodynamic instability 55 achieved CCyR 55 surgical revascularization 55 receptor blockers ARBs 55 p = .# [002] 55 chemoradiotherapy 55 ATACAND 55 malperfusion 55 aldosterone antagonists 55 HBeAg 55 mcg BID 55 laparotomy 55 K ras mutations 55 thrombolytic agents 55 lipid lowering agents 55 tumor progression TTP 55 interferon therapy 55 methotrexate monotherapy 55 sustained virologic response 55 tachyarrhythmias 55 CIMZIA TM certolizumab pegol 55 PaO 2 55 lumbar spine BMD 55 AST ALT 55 colorectal adenoma 55 somatostatin analog 55 placebo dexamethasone 55 DES implantation 55 achieved statistical significance 55 mitral stenosis 55 IIIa inhibitor 55 pericardial effusion 55 monotherapy 55 TURBT 55 HMG CoA reductase inhibitor 55 intra arterial 55 carotid stenosis 55 detemir 55 5FU 55 ventricular fibrillation 55 urinary albumin excretion 55 acutely decompensated congestive heart 55 oxycodone CR 55 riociguat 55 lactate dehydrogenase LDH 55 dose atorvastatin 55 fluticasone salmeterol 55 CK # plasma concentrations 55 glomerular filtration rate 55 serum potassium 55 surgical ventricular 55 RLAI 55 coronary stenoses 55 neoplastic cells 55 retinal thickness 55 glycoprotein IIb IIIa inhibitors 55 Psoriasis Area 55 RYGB 55 fasting plasma glucose 55 intravitreal injections 55 hypomagnesemia 55 hematological parameters 55 p = #.# [004] 55 mesalamine granules 55 GHRH 55 arterial thromboembolic events 55 lymphopenia 55 UPDRS 55 cardiopulmonary bypass CPB 55 nonoperative 55 Free Survival PFS 55 methacholine challenge 55 Postoperative complications 55 pulmonary artery banding 55 liver metastasis 55 8mg/kg 55 myocardial perfusion 55 acute STEMI 55 ischemia induced 55 ß blockers 55 mitoxantrone 55 titrated 55 undergoing coronary artery 55 plasma glucose levels 55 nonfatal myocardial infarction 55 repolarization 55 HIV HCV coinfected 55 divalproex sodium 55 fraction LVEF 55 nondiabetics 55 fibrinolytic 55 serum HCV RNA 55 thrombolytic therapy 55 edifoligide 55 sinus node dysfunction 55 recurrent ischemia 55 nephrectomy 55 aPTT 55 angiographic outcomes 55 hyperkalemia 55 external beam radiotherapy 55 cTnT 55 cranial irradiation 55 Catheter ablation 55 clomipramine 55 hemoglobin concentrations 55 peginterferon alfa 2a 55 haemodynamic 55 divalproex 55 nephrotoxicity 55 EDARBI 55 varices 55 TMP SMX 55 chloride secretion 55 tecarfarin 55 TAXUS stent 55 OGTT 55 plasma creatinine 55 refractory NSCLC 55 eGFR 55 COPD exacerbations 55 colorectal liver metastases 55 ventricular tachycardia 55 resynchronization therapy 55 gastric pH 55 mcg kg 55 nutlin 3a 55 transurethral resection 55 opioid analgesia 55 ropivacaine 55 definite stent thrombosis 55 partial onset seizures 55 serum HBV DNA 55 ICD shocks 55 thrombus aspiration 55 rCBF 55 glycosylated hemoglobin levels 55 apnea hypopnea index 55 low dose Iluvien 55 Kaplan Meier 55 left ventricular ejection 55 parenchymal 55 normotensive 55 sinus bradycardia 55 recurrent atrial fibrillation 55 budesonide formoterol 55 IIIa inhibitors 55 hemodynamics 55 COREG 55 interferon alfa 2b 55 salmeterol HFA MDI 55 poor metabolizers 55 hypotensive 55 cytogenetic response 55 CYPHER Stent 55 occluded artery 55 QTc interval 55 platelet aggregation 55 response CCyR 55 hemodynamic parameters 55 preoperative chemotherapy 55 prostate cancer CaP 55 LHRH agonist 55 Index CDAI 55 ventricular dyssynchrony 55 #mmHg [001] 55 peak VO2 55 ALT flares 55 sternotomy 54 Postoperatively 54 cirrhotic 54 hepatic function 54 evaluable 54 nortriptyline 54 serum estradiol 54 Abciximab 54 GH secretion 54 pharmacokinetic PK profile 54 ≥ 54 5-FU/LV 54 eosinophil count 54 Scale EDSS 54 lung resection 54 surgically induced 54 femoral shaft fracture 54 evaluable subjects 54 dose dependently 54 secondary efficacy endpoint 54 VIRAMUNE 54 mitral regurgitation 54 multivessel disease 54 ACE inhibitor ramipril 54 Ejection Fraction 54 HCV infected 54 detrusor overactivity 54 cilostazol 54 chest radiographs 54 Left Ventricular Ejection Fraction 54 low dose dexamethasone 54 arterial oxygen saturation 54 mycophenolate mofetil 54 mcg albinterferon alfa 2b 54 concomitant medications 54 LV ejection fraction 54 teriflunomide 54 adenotonsillectomy 54 μg liter 54 histologically 54 angiotensin converting enzyme inhibitors 54 recurrent venous thromboembolism 54 lopinavir r arm 54 bypass grafts 54 nonischemic 54 baroreflex 54 cystectomy 54 bioprostheses 54 serum sodium 54 serum triglyceride levels 54 de novo lesions 54 LANTUS R 54 hours postdose 54 NATRECOR R 54 azacitidine 54 infarct 54 clopidogrel 54 urinary N telopeptide 54 clopidogrel Plavix 54 antiarrhythmic medications 54 achieved ACR# 54 MMSE score 54 FOLPI 54 azathioprine 54 iodixanol 54 statistically significant p = 54 fulvestrant 54 antiarrhythmic 54 fosamprenavir 54 angiotensin converting enzyme inhibitor 54 arterial grafts 54 pulsatile flow 54 prescribed beta blocker 54 acute decompensation 54 hemorrhagic complications 54 hypophosphatemia 54 parathyroidectomy 54 #Gy 54 VcMP 54 dalteparin 54 prolactin levels 54 ARB telmisartan 54 follicular lymphomas 54 % CI #.#-#.# [007] 54 hyperoxia 54 generalized tonic clonic seizures 54 mg dose 54 cirrhotic patients 54 isolated systolic hypertension 54 otamixaban 54 nonfasting triglyceride levels 54 conventional angiography 54 lung metastasis 54 tolterodine 54 hypogonadal 54 adenoidectomy 54 response pCR 54 detectable HCV RNA 54 sustained virological response 54 intravenous dosing 54 CTEPH 54 luminal diameter 54 MADRS score 54 CRT Ds 54 cardiovascular hospitalizations 54 plasma cortisol 54 NNT = 54 trandolapril 54 ketorolac 54 myocardial ischemia 54 warfarin therapy 54 GOUT 54 Hb 54 IL 1ß 54 Natalizumab 54 torsade de pointes 54 Ventricular 54 hypovolemic 54 NovoLog ® Mix 54 onset diabetes mellitus 54 peginterferon alfa 2b 54 MetS 54 hyperphenylalaninemia HPA due 54 vWF 54 patients undergoing CABG 54 dexamethasone 54 n = 54 prospectively stratified 54 dyssynchrony 54 Doppler sonography 54 plus methotrexate 54 clinically meaningful reductions 54 retinal vein occlusion 54 aortic root replacement 54 hMG 54 cellular prion protein 54 adjuvant tamoxifen 54 contrast induced nephropathy 54 AGHD 54 KRAS mutations occur 54 pyridostigmine 54 lactate dehydrogenase 54 ACTIVE W 54 ARIXTRA 54 biventricular 54 neurocognitive function 54 antithrombotic therapy 54 vecuronium 54 clinically meaningful improvements 54 advanced adenomas 54 left ventricular hypertrophy 54 streptokinase 54 mg TID 54 neuroleptic 54 fluorouracil 54 multivariable analysis 54 candesartan 54 CorVue ™ 54 DHCA 54 carotid artery stenting 54 LEXIVA 54 thrombocytosis 54 FOLFIRI 54 elevated ALT 54 IGFBP 3 54 remifentanil 54 choroidal neovascularization 54 glycosylated hemoglobin 54 intravenous morphine 54 Thrombolysis 54 curative resection 54 transplant ASCT 54 = #.#-#.# 54 cardiopulmonary bypass 54 tachycardias 54 CR CRu 54 TURP 54 chemoradiation therapy 54 pulmonary artery pressure 54 Operative mortality 54 mCRC patients 54 intravenous bolus 54 typical antipsychotics 54 milrinone 54 oral hypoglycemic agents 54 Median PFS 54 mg BID 54 neovascularization 54 NATRECOR ® 54 acute coronary syndromes ACS 54 arteriography 54 ischemic lesions 54 clodronate 54 myocytes 54 leukocytosis 54 candesartan cilexetil 54 trough FEV1 54 ventricular remodeling 54 unstable angina UA 54 baseline HbA1c 54 HbA1C levels 54 amenorrhoea 54 gout flares 54 darunavir ritonavir 54 OAB symptoms 54 hematologic toxicity 54 diastolic BP 54 ABVD 54 oral antidiabetes 54 natriuresis 54 valve regurgitation 54 tamponade 54 splenectomized patients 54 coronary occlusion 54 ovulatory 54 vagal 54 ventricular dilatation 54 nadroparin 54 verapamil 54 GG genotype 54 lavage 54 interferon ribavirin 54 primidone 54 GH deficient 54 glycated hemoglobin 54 simvastatin ezetimibe 54 downregulated 54 IGFBP 54 SCIg 54 invasive aspergillosis 54 ventricular tachyarrhythmia 54 defibrillator CRT D 54 plasma viremia 54 PROMACTA 54 myocardial fibrosis 54 NT proBNP 54 antiplatelet medication 54 HGPIN 54 dose escalation phase 54 silent ischemia 54 severe hypoglycemia 54 oral anticoagulant therapy 54 piperacillin tazobactam 54 hemodynamic 54 composite endpoint 54 endothelium dependent 54 moderate renal impairment 54 noncardiac 54 Percutaneous Coronary Intervention 54 virologic response 54 antral 54 carotid IMT 54 thyroxine 54 diastolic heart 54 RAS inhibitors 54 imatinib 54 ventricular tachyarrhythmias 54 urinary albumin 54 catheter ablation 54 uncoated stent 54 pneumonectomy 54 lumbar spine bone 54 Brief Psychiatric 54 ventilatory 54 hypertensives 54 nonsignificant 53 aneurysm ruptures 53 spirometric 53 EGFR TKI 53 GIK infusion 53 ACE Inhibitor 53 euthymic patients 53 hepatectomy 53 ventricular pacing 53 remission induction 53 osteoblast 53 C1 INH 53 glatiramer acetate 53 ml kg 53 alkaline phosphatase ALP 53 vasospasm 53 captopril 53 bolus dose 53 antimicrobial prophylaxis 53 MADIT II 53 lung metastases 53 microcirculatory improvement helping 53 HER2 expression 53 aortic regurgitation 53 ventricular arrhythmia 53 #.#/#.# mmHg [001] 53 locoregional disease 53 lispro alone 53 superficial femoral 53 mg/m2 dose 53 secondary endpoint 53 glycated hemoglobin HbA1c 53 asthma exacerbation 53 ERK1 2 53 concomitant antibiotics 53 dual antiplatelet therapy 53 primary aldosteronism 53 HBV DNA 53 hepatic enzyme 53 mcg kg min 53 tipranavir r 53 carotid endarterectomy 53 mg dL 53 alpha blocker 53 preserved systolic 53 ritonavir boosted 53 coinfected patients 53 steroid dexamethasone